Puma Biotechnology Interest Expense 2011-2026 | PBYI

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Puma Biotechnology

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
1.03 M	862 K	759 K	-28 K	12.8 M	14 M	15 M	11 M	720 K	-373 K	25 K	-14 K	2 K	-	-80 K

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
15 M	-373 K	3.98 M

Quarterly Interest Expense Puma Biotechnology

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
115 K	410 K	359 K	-	347 K	156 K	91 K	-	74 K	86 K	3.31 M	-	2.95 M	2.7 M	2.66 M	-	3.12 M	3.52 M	3.45 M	-	3.63 M	3.78 M	3.07 M	-	3.05 M	4.45 M	4.44 M	-	3.5 M	2.59 M	1.08 M	-	-45 K	-30 K	-13 K	-	4 K	-376 K	-8 K	-	-2 K	6 K	22 K	-	4 K	-5 K	-21 K	-	39 K	-39 K	3 K	-	-	-	-	-	-13.5 K	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
4.45 M	-376 K	1.31 M

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Arbutus Biopharma Corporation ABUS	459 K	$ 4.5	0.45 %	$ 862 M	Canada
Agenus AGEN	72.4 M	$ 3.64	9.31 %	$ 108 M	USA
Agios Pharmaceuticals AGIO	1.96 M	$ 35.08	-0.36 %	$ 2.03 B	USA
Akebia Therapeutics AKBA	58 K	$ 1.39	0.36 %	$ 357 M	USA
Akari Therapeutics, Plc AKTX	100 K	$ 3.95	-11.63 %	$ 266 B	Britain
I-Mab IMAB	722 K	-	-	$ 866 M	China
Genfit SA GNFT	4.68 M	-	2.54 %	$ 160 B	France
Aldeyra Therapeutics ALDX	1.69 M	$ 1.57	-5.42 %	$ 94.3 M	USA
Aligos Therapeutics ALGS	2.2 M	$ 8.08	1.38 %	$ 79.9 M	USA
Alnylam Pharmaceuticals ALNY	5.2 M	$ 331.14	3.85 %	$ 43.4 B	USA
Altimmune ALT	-190 K	$ 3.4	1.8 %	$ 300 M	USA
ALX Oncology Holdings ALXO	1.6 M	$ 1.99	0.81 %	$ 107 M	USA
Amneal Pharmaceuticals AMRX	16.5 M	$ 12.27	-1.68 %	$ 3.85 B	USA
Acorda Therapeutics ACOR	31.5 M	-	-24.86 %	$ 820 K	USA
ANI Pharmaceuticals ANIP	-4.03 M	$ 73.8	-0.55 %	$ 1.43 B	USA
Annexon ANNX	57 K	$ 5.56	1.0 %	$ 862 M	USA
Adverum Biotechnologies ADVM	8.23 M	-	-	$ 86.2 M	USA
Advaxis ADXS	28 K	-	-9.65 %	$ 45.9 M	USA
Applied Molecular Transport AMTI	-4 K	-	-	$ 10.1 M	USA
Aprea Therapeutics APRE	634 K	$ 0.7	-1.87 %	$ 4.58 M	USA
Aquestive Therapeutics AQST	6.55 M	$ 4.12	-0.24 %	$ 441 M	USA
AgeX Therapeutics AGE	51 K	-	-10.17 %	$ 12.2 K	USA
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
Arcturus Therapeutics Holdings ARCT	10.1 M	$ 8.14	1.31 %	$ 223 M	Israel
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
Ardelyx ARDX	4.5 M	$ 5.99	0.84 %	$ 1.44 B	USA
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
Akouos AKUS	-1.72 M	-	0.23 %	$ 488 M	USA
Arcutis Biotherapeutics ARQT	443 K	$ 24.06	1.82 %	$ 3.06 B	USA
Arvinas ARVN	-400 K	$ 10.87	0.14 %	$ 771 M	USA
Arrowhead Pharmaceuticals ARWR	5.26 M	$ 60.28	-1.23 %	$ 8.06 B	USA
Allena Pharmaceuticals ALNA	-38 K	-	3.16 %	$ 1.9 M	USA
Assembly Biosciences ASMB	117 K	$ 29.51	1.72 %	$ 331 M	USA
Alpine Immune Sciences ALPN	476 K	-	-	$ 2.17 B	USA
Aileron Therapeutics ALRN	48 K	-	10.36 %	$ 9.8 M	USA
Alterity Therapeutics Limited ATHE	2.28 K	$ 3.62	1.82 %	$ 8.71 B	Australia